| Literature DB >> 35152892 |
Yvonne A C Bekker1, Ankie F Suntjens1, Y Engels2, H Schers3, Gert P Westert1, A Stef Groenewoud4.
Abstract
BACKGROUND: Advance Care Planning (ACP) enables physicians to align healthcare with patients' wishes, reduces burdensome life-prolonging medical interventions, and potentially improves the quality of life of patients in the last phase of life. However, little objective information is available about the extent to which structured ACP conversations are held in general practice. Our aim was to examine the documentation of ACP for patients with cancer, organ failure and multimorbidity in medical records (as a proxy for ACP application) in Dutch general practice.Entities:
Keywords: Advance care planning; End of life care; General practice; General practitioner; Medical records; Primary care
Mesh:
Year: 2022 PMID: 35152892 PMCID: PMC8842525 DOI: 10.1186/s12904-022-00907-6
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
Fig. 1Selection of patients who died non-suddenly of ‘cancer’, ‘organ failure’ or ‘multimorbidity’ in general practice
Patient characteristics and healthcare use in the last two years of life (subgroup analyses for cancer, organ failure and multimorbidity patients)
| General characteristics | Total | Cancer | Organ failure | Multimorbidity | |
|---|---|---|---|---|---|
| Gender female, n (%) | 61 (51) | 29 (53) | 14 (50) | 18 (50) | 0.957* |
| Age at time of death, mean (SD) | 79 (14) | 70 (14) | 84 (8) | 88 (7) | 0.000** |
| Place of death, n (%) | 0.088*** | ||||
| Home | 70 (59) | 35 (64) | 16 (57) | 19 (53) | |
| Hospital | 32 (27) | 11 (20) | 7 (25) | 14 (39) | |
| Hospice | 6 (5) | 6 (11) | 0 (0) | 0 (0) | |
| Long-term care facility | 4 (3) | 1 (2) | 1 (4) | 2 (6) | |
| Unknown | 7 (6) | 2 (4) | 4 (14) | 1 (3) | |
| EoL support, n (%) | |||||
| Palliative sedation | 32 (27) | 22 (40) | 2 (7) | 8 (22) | 0.005* |
| Euthanasia/assisted suicide | 5 (4) | 5 (9) | 0 (0) | 0 (0) | 0.085*** |
| Healthcare use, median (25th–75th percentile, range) | |||||
| Number of hospitalizations | 1 (0–3, 0–15) | 2 (1–3, 0–11) | 2 (1–4, 0–15) | 0,5 (0–1, 0–4) | 0.000** |
| Number of ED visits | 1 (0–2, 0–9) | 1 (0–3, 0–6) | 2 (1–3, 0–9) | 1 (0–1, 0–6) | 0.006** |
| Number of GP out of office hours contacts | 1 (0–4, 0–22) | 1 (0–4, 0–22) | 2 (0–5, 0–6) | 1 (0–2, 0–8) | 0.316** |
* Chi Square test
** Kruskal Wallis test
*** Fisher’s Exact test
**** Mann Whitney U test
Prevalence and characteristics of Advance Care Planning by GP (subgroup analyses for cancer, organ failure and multimorbidity patients)
| Prevalence of ACP (documentation) | Total | Cancer | Organ failure | Multimorbidity | |
|---|---|---|---|---|---|
| Prevalence (≥ 1 ACP item), n (%) | 77 (65) | 46 (84) | 16 (57) | 15 (42) | 0.000* |
Total ( | Cancer ( | Organ failure ( | Multimorbidity ( | ||
| Extent | |||||
| Number of ACP items, median (25th -75th percentile, range) | 4 (2–7, 1–11) | 5 (2–7, 1–11) | 3,5 (2–6, 1–8) | 2 (1–5, 1–7) | 0.047** |
| Subclassification: | 0.222*** | ||||
| Low (1 or 2 items) | 29 (38) | 15 (33) | 6 (38) | 8 (53) | |
| Medium (3, 4 or 5 items) | 26 (34) | 14 (30) | 6 (38) | 6 (40) | |
| High (≥ 6 ACP items) | 22 (29) | 17 (37) | 4 (25) | 1 (7) | |
| Frequency | |||||
| Number of ACP conversations, median (25th–75th percentile, range) | 3 (1–4, 1–14) | 3 (2–5, 1–14) | 2 (1–3, 1–7) | 2 (1–3, 1–4) | 0.012** |
| Timing | |||||
| Time between first ACP conversation and death in days, median (25th–75th percentile, range) | 126 (30–316, 1–714) | 106 (22–307, 3–680) | 227 (39–395, 1–714) | 113 (52–320, 10–529) | 0.417** |
* Chi Square test, ** Kruskal Wallis test, *** Fisher’s Exact test
Post-hoc tests on differences between groups of patients
| Cancer vs Organ failure | Cancer vs multimorbidity | Organ failure vs multimorbidity | |
|---|---|---|---|
| Prevalence (≥ 1 ACP item documented) | 0.015* | 0.000* | 0.314* |
| Extent (number of ACP items) | 0.417**** | 0.023**** | 0.175**** |
| Frequency (number of ACP conversations) | 0.043**** | 0.010**** | 0.520**** |
* Chi Square test
**** Mann Whitney U test
Fig. 2Prevalence and extensiveness of ACP (number of ACP items documented) for all patients and sub-groups, in percentages
ACP content as documented by GPs (subgroup analyses for cancer, organ failure and multimorbidity patients)
| Items of ACP | Total | Cancer | Organ failure | Multimorbidity | |
|---|---|---|---|---|---|
| Documented treatment preferences for future care, n (%) | |||||
| Resuscitation | 25 (21) | 11 (20) | 11 (39) | 3 (8) | 0.009 |
| Mechanical ventilation | 2 (2) | 2 (4) | 0 (0) | 0 (0) | 0.499 |
| Intensive Care Unit admission | 4 (3) | 2 (4) | 2 (7) | 0 (0) | 0.266 |
| Referral to ED and hospitalization | 22 (19) | 8 (15) | 8 (29) | 6 (17) | 0.286 |
| Antibiotics | 4 (3) | 2 (4) | 1 (4) | 1 (3) | 1.000 |
| Artificial feeding and liquid administration | 1 (1) | 1 (2) | 0 (0) | 0 (0) | 1.000 |
| Other treatment preferences | 18 (15) | 11 (20) | 4 (14) | 3 (8) | 0.308 |
| Documented EoL wishes, n (%) | |||||
| Preferred place of care/death | 35 (29) | 20 (36) | 7 (25) | 8 (22) | 0.327 |
| Personal wishes/goals | 18 (15) | 16 (29) | 1 (4) | 1 (3) | 0.000 |
| Discussed future scenarios, n (%) | |||||
| Prognosis/life expectancy | 29 (24) | 18 (33) | 8 (29) | 3 (8) | 0.024 |
| Disease specific future scenarios | 20 (17) | 16 (29) | 3 (11) | 1 (3) | 0.002 |
| Concerns and hopes towards future | 34 (29) | 20 (36) | 7 (25) | 7 (19) | 0.206 |
| Conversation about palliative sedation | 27 (23) | 22 (40) | 4 (14) | 1 (3) | 0.000 |
| Conversation about euthanasia | 42 (35) | 35 (64) | 2 (7) | 5 (14) | 0.000 |
| Conversation ‘end-of-life’ | 22 (19) | 14 (26) | 5 (18) | 3 (8) | 0.136 |
| Registered advance directives, n (%) | |||||
| Declaration of will | 19 (16) | 18 (33) | 0 (0) | 1 (3) | 0.000 |
| Appointment of legal representative | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
Content of ACP in correspondence of other healthcare provider (subgroup analyses for cancer, organ failure and multimorbidity patients)
| Items of ACP | Total | Cancer | Organ failure | Multimorbidity | |
|---|---|---|---|---|---|
| Documented treatment preferences for future care, n (%) | |||||
| Resuscitation | 33 (28) | 16 (29) | 11 (39) | 6 (17) | 0.129 |
| Mechanical ventilation | 9 (8) | 7 (13) | 1 (4) | 1 (3) | 0.150 |
| Intensive Care Unit admission | 20 (17) | 9 (16) | 9 (32) | 2 (6) | 0.019 |
| Referral to ED and hospitalization | 7 (6) | 3 (6) | 3 (11) | 1 (3) | 0.470 |
| Antibiotics | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
| Artificial feeding and liquid administration | 1 (1) | 1 (2) | 0 (0) | 0 (0) | 1.000 |
| Other treatment preferences | 13 (11) | 9 (16) | 3 (11) | 1 (3) | 0.119 |
| Documented EoL wishes, n (%) | |||||
| Preferred place of care/death | 11 (9) | 8 (15) | 1 (4) | 2 (6) | 0.272 |
| Personal wishes/goals | 5 (4) | 4 (7) | 1 (4) | 0 (0) | 0.199 |
| Discussed future scenarios, n (%) | |||||
| Prognosis/life expectancy | 25 (21) | 21 (38) | 3 (11) | 1 (3) | 0.000 |
| Disease specific future scenarios | 13 (11) | 11 (20) | 1 (4) | 1 (3) | 0.017 |
| Concerns and hopes towards future | 5 (4) | 4 (7) | 0 (0) | 1 (3) | 0.439 |
| Conversation about palliative sedation | 4 (3) | 3 (6) | 1 (4) | 0 (0) | 0.358 |
| Conversation about euthanasia | 8 (7) | 6 (11) | 1 (4) | 1 (3) | 0.319 |
| Conversation ‘end-of-life’ | 2 (2) | 2 (4) | 0 (0) | 0 (0) | 0.499 |
Barriers for the uptake of ACP, as reported in the literature
Despite the fact that there is increasing attention for ACP and a growing body of evidence of its positive effects, research shows that the application of ACP conversations remains still low, and the organization and delivery of healthcare is still predominantly reactive [ Several barriers have been reported that may prevent optimal implementation in clinical practice. First, on the patient-side, participation is at risk in case patients are not ready to talk about themes related to deterioration in their condition or the nearing death [ |